Ceritinib
别名: LDK378
目录号:S7083 Purity: 99.96%
Ceritinib是一种有效的ALK抑制剂,在无细胞试验中IC50为0.2 nM。Ceritinib (LDK378)还可抑制IGF-1R、InsR、STK22D和FLT3对应的IC50值分别为8 nM、7 nM、23 nM和60 nM。Phase 3。
CAS: 1032900-25-6
客户使用Selleck的Ceritinib发表文献112篇
- Cancer Discov, 2024 OF1-OF20.
- Nat Cancer, 2022 3(6):710-722
- Nature, 2021 600(7888):319-323
- Cell, 2021 184(10):2649-2664.e18
- Cancer Cell, 2020 38(1):44-59.e9
- Cancer Discov, 2020 1 pii: CD-19-1030
- J Thorac Oncol, 2020 15(5):752-765
- Nature, 2019 10.1038/s41586-019-1472-0
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Cancer Discov, 2018 8(6):714-729
- Blood, 2018 131(14):1576-1586
- Cancer Discov, 2016 6(10):1118-1133
- Nat Med, 2015 21(9):1038-47
- Cancer Cell, 2015 27(3):397-408
- Cell Res, 2015 10.1038/cr.2015.16
- Nat Med, 2014 20(9):1027-34
- Nat Commun, 2024 15(1):51
- Commun Biol, 2024 7(1):412
- iScience, 2024 27(2):109015.
- Clin Cancer Res, 2023 29(7):1317-1331
- Clin Cancer Res, 2023 29(5):943-956
- Biomolecules, 2023 13(3)438
- Front Oncol, 2023 13:1184900
- J Neurooncol, 2023 162(1):109-118.
- Invest New Drugs, 2023 41(2):254-266
- Cancer Res Commun, 2023 3(12):2608-2622
- Exp Mol Med, 2022 54(8):1236-1249
- Exp Mol Med, 2022 54(8):1225-1235
- Cancer Res, 2022 82(2):307-319
- NPJ Precis Oncol, 2022 6(1):11
- Mol Oncol, 2022 10.1002/1878-0261.13318
- Cell Oncol (Dordr), 2022 45(5):991-1003
- Front Pharmacol, 2022 13:1032975
- Lung Cancer, 2022 171:103-114
- Cancers (Basel), 2022 14(3)779
- Mol Cancer Res, 2022 20(6):854-866
- J Pers Med, 2022 12(2)258
- Sci Rep, 2022 12(1):6345
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- BMC Cancer, 2022 22(1):752
- Cancer Res Commun, 2022 2(5):277-285
- Clin Cancer Res, 2021 27(9):2533-2548
- Cell Death Dis, 2021 12(8):713
- Cell Rep, 2021 36(7):109515
- EMBO Rep, 2021 22(12):e53693
- ESMO Open, 2021 6(4):100172
- Mol Cancer Ther, 2021 molcanther.0221.2021
- Cancers (Basel), 2021 13(17)4422
- Sci Rep, 2021 11(1):9011
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Endocr Relat Cancer, 2021 28(6):377-389
- Cereb Cortex, 2021 bhab058
- Oncol Lett, 2021 21(5):418
- Jpn J Clin Oncol, 2021 hyab048
- Genome Med, 2020 18;12(1):17
- Clin Cancer Res, 2020 8
- EMBO Mol Med, 2020 e11099
- Cell Rep, 2020 31(12):107800
- Acta Pharmacol Sin, 2020 10.1038/s41401-020-00513-3
- Oncogene, 2020 39(1):151-163
- Int J Mol Sci, 2020 21(9)E3214
- Cancers (Basel), 2020 24;12(4) pii: E1054
- Cancers (Basel), 2020 26;12(4)
- Sci Rep, 2020 10(1):218
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Oncol Rep, 2020 44(6):2581-2594
- Nat Commun, 2019 10(1):4343
- EMBO Mol Med, 2019 10.15252/emmm.201910581
- Cancer Immunol Res, 2019
- Cell Syst, 2019 8(2):97-108
- Oncogene, 2019 101038/s41388-019-1136-4
- Int J Mol Sci, 2019 20(17)
- Cancers (Basel), 2019 11(1)E104
- Sci Rep, 2019
- Biochem J, 2019 10.1042/BCJ20190106
- Invest New Drugs, 2019 10.1007/s10637-019-00795-3
- Invest New Drugs, 2019 10.1007/s10637-019-00802-7
- Cell Death Differ, 2018 25(12):2053-2070
- Clin Cancer Res, 2018 24(17):4162-4174
- Clin Cancer Res, 2018 24(23):6066-6077
- Cancer Res, 2018 78(24):6866-6880
- Sci Signal, 2018 11(557)
- Mol Cancer Ther, 2018 17(11-:2271-2284
- Cancer Sci, 2018 109(10):3149-3158
- Mol Cancer Ther, 2018 17(1):222-231
- Mol Cancer Ther, 2018 17(1):73-83
- Oncotarget, 2018 9(43-:27242-27255
- Mol Pharm, 2018 15(5):1892-1900
- Development, 2018 145(20)dev164046
- Cell Physiol Biochem, 2018 46(6):2487-2499
- Onco Targets Ther, 2018 11:8201-8209
- Cancer Chemother Pharmacol, 2018 82(2):251-263
- Sci Transl Med, 2017 14;9(394):eaah6144
- Cell Rep, 2017 21(11):3298-3309
- J Pathol, 2017 243(3):307-319
- Arch Toxicol, 2017 91(8):2921-2938
- Cancer Sci, 2017
- Oncotarget, 2017 8(35):58771-58780
- Cancers (Basel), 2017 9(11)E149
- Anticancer Drugs, 2017 28(10):1118-1125
- Oncogene, 2016 35(28):3681-91
- J Pathol, 2016 238(4):543-9
- Oncoimmunology, 2016 5(3):e1094598
- Sci Rep, 2016 10.1038/srep24817
- Sci Rep, 2016 6:33710
- Cell Physiol Biochem, 2016 40(5):1129-1140
- Mol Oncol, 2015 10.1016/j.molonc.2015.11.007
- Oncotarget, 2015 6(42):44643-59
- Biochem Biophys Res Commun, 2014 454(4):566-571
化学信息&溶解度
分子量 | 558.14 |
分子式 | C28H36ClN5O3S |
CAS号 | 1032900-25-6 |
Smiles | CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 4 mg/mL ( 7.16 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 20 mg/mL ( 35.83 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 3 mg/mL Water : Insoluble Ethanol : 5 mg/mL DMSO : 3 mg/mL ( 5.37 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:0.15mg/ml
(0.27mM)
操作示例:以 1 mL 工作液为例,取50μL3mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。